» Articles » PMID: 15814707

Increased Immunogenicity of an Anchor-modified Tumor-associated Antigen is Due to the Enhanced Stability of the Peptide/MHC Complex: Implications for Vaccine Design

Overview
Journal J Immunol
Date 2005 Apr 9
PMID 15814707
Citations 63
Authors
Affiliations
Soon will be listed here.
Abstract

The use of "anchor-fixed" altered peptide ligands is of considerable interest in the development of therapeutic vaccines for cancer and infectious diseases, but the mechanism by which successful altered peptide ligands elicit enhanced immunity is unclear. In this study, we have determined the crystallographic structure of a major tumor rejection Ag, gp100(209-217), in complex with the HLA-A*0201 (HLA-A2) molecule, as well as the structure of a modified version of the peptide which substitutes methionine for threonine at position 2 (T2M; gp100(209-2M)). The T2M-modified peptide, which is more immunogenic in vitro and in vivo, binds HLA-A2 with a approximately 9-fold greater affinity and has a approximately 7-fold slower dissociation rate at physiological temperature. Within the limit of the crystallographic data, the T2M substitution does not alter the structure of the peptide/HLA-A2 complex. Consistent with this finding, in peripheral blood from 95 human subjects, we were unable to identify higher frequencies of T cells specific for either the native or modified peptide. These data strongly support the conclusion that the greater immunogenicity of the gp100(209-2M) peptide is due to the enhanced stability of the peptide/MHC complex, validating the anchor-fixing approach for generating therapeutic vaccine candidates. Thermodynamic data suggest that the enhanced stability of the T2M-modified peptide/HLA-A2 complex is attributable to the increased hydrophobicity of the modified peptide, but the gain due to hydrophobicity is offset considerably by the loss of a hydrogen bond made by the native peptide to the HLA-A2 molecule. Our findings have broad implications for the optimization of current vaccine-design strategies.

Citing Articles

The Evolving T Cell Receptor Recognition Code: The Rules Are More Like Guidelines.

Gray G, Chukwuma P, Eldaly B, Perera W, Brambley C, Rosales T Immunol Rev. 2025; 329(1):e13439.

PMID: 39804137 PMC: 11771984. DOI: 10.1111/imr.13439.


Mutations in glioblastoma proteins do not disrupt epitope presentation and recognition, maintaining a specific CD8 T cell immune response potential.

Tarabini R, Vieira G, Rigo M, Souza A Sci Rep. 2024; 14(1):16721.

PMID: 39030304 PMC: 11271619. DOI: 10.1038/s41598-024-67099-2.


Unconventional modes of peptide-HLA-I presentation change the rules of TCR engagement.

Hopkins J, MacLachlan B, Harper S, Sewell A, Cole D Discov Immunol. 2024; 1(1):kyac001.

PMID: 38566908 PMC: 10917088. DOI: 10.1093/discim/kyac001.


APE-Gen2.0: Expanding Rapid Class I Peptide-Major Histocompatibility Complex Modeling to Post-Translational Modifications and Noncanonical Peptide Geometries.

Fasoulis R, Rigo M, Lizee G, Antunes D, Kavraki L J Chem Inf Model. 2024; 64(5):1730-1750.

PMID: 38415656 PMC: 10936522. DOI: 10.1021/acs.jcim.3c01667.


Seeing the T cell Immunity of SARS-CoV-2 and SARS-CoV: Believing the Epitope-Oriented Vaccines.

Yue C, Wang P, Tian J, Gao G, Liu K, Liu W Int J Biol Sci. 2023; 19(13):4052-4060.

PMID: 37705735 PMC: 10496500. DOI: 10.7150/ijbs.80468.


References
1.
McRee D . XtalView/Xfit--A versatile program for manipulating atomic coordinates and electron density. J Struct Biol. 1999; 125(2-3):156-65. DOI: 10.1006/jsbi.1999.4094. View

2.
Irvine K, Parkhurst M, Shulman E, Tupesis J, Custer M, Touloukian C . Recombinant virus vaccination against "self" antigens using anchor-fixed immunogens. Cancer Res. 1999; 59(11):2536-40. PMC: 2249691. View

3.
Ding Y, Baker B, Garboczi D, Biddison W, Wiley D . Four A6-TCR/peptide/HLA-A2 structures that generate very different T cell signals are nearly identical. Immunity. 1999; 11(1):45-56. DOI: 10.1016/s1074-7613(00)80080-1. View

4.
Gakamsky D, Boyd L, Margulies D, Davis D, Strominger J, Pecht I . An allosteric mechanism controls antigen presentation by the H-2K(b) complex. Biochemistry. 1999; 38(37):12165-73. DOI: 10.1021/bi9905821. View

5.
Kuhns J, Batalia M, Yan S, Collins E . Poor binding of a HER-2/neu epitope (GP2) to HLA-A2.1 is due to a lack of interactions with the center of the peptide. J Biol Chem. 1999; 274(51):36422-7. DOI: 10.1074/jbc.274.51.36422. View